13-Dec-2024
No headlines found.
Charles River Introduces Global Biotech Incubator Program
Business Wire (Thu, 5-Dec 8:00 AM ET)
Charles River Laboratories to Present at Evercore ISI Investor Conference
Business Wire (Mon, 2-Dec 8:00 AM ET)
Charles River Laboratories to Present at UBS and Jefferies Conferences
Business Wire (Mon, 11-Nov 8:00 AM ET)
Charles River Laboratories Announces Third-Quarter 2024 Results
Business Wire (Wed, 6-Nov 7:00 AM ET)
Charles River Launches New Retrogenix Non-Human Protein Library
Business Wire (Thu, 17-Oct 8:00 AM ET)
Charles River Laboratories Schedules Third-Quarter 2024 Earnings Release and Conference Call
Business Wire (Wed, 16-Oct 4:30 PM ET)
Charles River Provides Translational Expertise at Neuroscience 2024
Business Wire (Thu, 3-Oct 8:00 AM ET)
Business Wire (Wed, 2-Oct 8:00 AM ET)
Business Wire (Tue, 17-Sep 8:00 AM ET)
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Charles River Laboratories International trades on the NYSE stock market under the symbol CRL.
As of December 13, 2024, CRL stock price declined to $190.46 with 510,261 million shares trading.
CRL has a beta of 1.73, meaning it tends to be more sensitive to market movements. CRL has a correlation of 0.26 to the broad based SPY ETF.
CRL has a market cap of $9.81 billion. This is considered a Mid Cap stock.
Last quarter Charles River Laboratories International reported $1 billion in Revenue and $2.59 earnings per share. This beat revenue expectation by $32 million and exceeded earnings estimates by $.16.
In the last 3 years, CRL traded as high as $379.65 and as low as $161.65.
The top ETF exchange traded funds that CRL belongs to (by Net Assets): VTI, VOO, VB, RSP, VBK.
CRL has underperformed the market in the last year with a price return of -12.6% while the SPY ETF gained +29.9%. CRL has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -4.1% and -4.3%, respectively, while the SPY returned +7.8% and +0.3%, respectively.
CRL support price is $189.57 and resistance is $198.97 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRL shares will trade within this expected range on the day.